Overexpression of human telomerase reverse transcriptase C-terminal polypeptide sensitizes HeLa cells to 5-fluorouracil‑induced growth inhibition and apoptosis

Lin,Guimiao; Chen,Qiang; Yu,Shuihong; Lin,Suxia; Yao,Hong; Ding,Zhangchi; Chen,Siping; Lin,Marie  Chia-Mi; Wang,Xiaomei

doi:10.3892/mmr.2013.1777

Overexpression of human telomerase reverse transcriptase C-terminal polypeptide sensitizes HeLa cells to 5-fluorouracil‑induced growth inhibition and apoptosis

Authors:
- Guimiao Lin
- Qiang Chen
- Shuihong Yu
- Suxia Lin
- Hong Yao
- Zhangchi Ding
- Siping Chen
- Marie Chia-Mi Lin
- Xiaomei Wang
View Affiliations

Affiliations: The Engineering Lab of Synthetic Biology and the Key Lab of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen, Guangdong 518060, P.R. China, School of Biomedical Science and State Key Laboratory in Oncology in South China, Chinese University of Hong Kong, Shatin, Hong Kong 999077, P.R. China
Published online on: November 5, 2013 https://doi.org/10.3892/mmr.2013.1777
Pages: 279-284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

5‑Fluorouracil (5‑FU) is a commonly used anti‑tumor chemotherapeutic drug for cervical carcinoma. However, increased drug resistance may occur following several cycles of 5‑FU‑based chemotherapy. Novel strategies of gene therapy for enhancing the sensitivity of cancer cells to 5‑FU chemotherapy have been intensively explored. Human telomerase reverse transcriptase (hTERT)C27 is a newly constructed hTERT C‑terminal polypeptide that is capable of promoting chromosome end‑to‑end fusion during anaphase and inducing telomere dysfunction. In the present study, the effects of hTERTC27 overexpression on 5‑FU‑induced proliferation inhibition and apoptosis were observed. HeLa cells were cultured and transfected with the constructed pcDNA3.1 or pcDNA3.1‑hTERTC27 vectors. Expression of hTERTC27 was detected using western blot analysis and was assessed using MTT assays and flow cytometry. The results demonstrated that overexpressed hTERTC27 increased the sensitivity of the HeLa cells to 5‑FU and significantly inhibited HeLa cell proliferation with 5‑FU treatment. In addition, hTERTC27 overexpression evidently promoted the 5‑FU‑induced apoptosis by increasing the expression of activated caspase‑3 and ‑9 and by downregulating the expression of B‑cell lymphoma 2. The results suggest that hTERTC27 overexpression is a potential clinical strategy for enhancing the antitumor effect of 5‑FU chemotherapy in the treatment of cervical carcinoma.

View Figures

View References

1	Markman M: Chemoradiation in the management of cervix cancer: current status and future directions. Oncology. 84:246–250. 2013. View Article : Google Scholar : PubMed/NCBI
2	Hemaiswarya S and Doble M: Combination of phenylpropanoids with 5-fluorouracil as anti-cancer agents against human cervical cancer (HeLa) cell line. Phytomedicine. 20:151–158. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yamamoto K, Fujiwara Y, Nishida T, et al: Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer Res. 29:4211–4215. 2009.PubMed/NCBI
4	Osaka Y, Shinohara M, Hoshino S, Ogata T, Takagi Y, Tsuchida A and Aoki T: Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res. 31:633–638. 2011.
5	Nagata M, Nakayama H, Tanaka T, et al: Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma. Br J Cancer. 105:1322–1330. 2011. View Article : Google Scholar : PubMed/NCBI
6	Wang CJ, Stratmann J, Zhou ZG and Sun XF: Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer. 10:6162010. View Article : Google Scholar : PubMed/NCBI
7	Karasawa H, Miura K, Fujibuchi W, et al: Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci. 100:903–913. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lin G, Lin MC, Lin S, et al: Early growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-fluorouracil on nasopharyngeal carcinoma. Cancer Biother Radiopharm. 27:434–441. 2012. View Article : Google Scholar : PubMed/NCBI
9	Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD and Alonso DF: Telomere structure and telomerase in health and disease (Review). Int J Oncol. 41:1561–1569. 2012.PubMed/NCBI
10	Shay JW and Wright WE: Role of telomeres and telomerase in cancer. Semin Cancer Biol. 21:349–353. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ruden M and Puri N: Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 39:444–456. 2013. View Article : Google Scholar : PubMed/NCBI
12	Podlevsky JD and Chen JJ: It all comes together at the ends: telomerase structure, function, and biogenesis. Mutat Res. 730:3–11. 2012. View Article : Google Scholar : PubMed/NCBI
13	Huang JJ, Lin MC, Bai YX, et al: Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res. 62:3226–3232. 2002.
14	Huang J, Bai YX, Han SW, et al: A human TERT C-terminal polypeptide sensitizes HeLa cells to H₂O₂-induced senescence without affecting telomerase enzymatic activity. Biochem Biophys Res Commun. 301:627–632. 2003. View Article : Google Scholar : PubMed/NCBI
15	Ng SS, Gao Y, Chau DH, et al: A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther. 14:561–572. 2007. View Article : Google Scholar : PubMed/NCBI
16	Gao Y, Ng SS, Chau DH, et al: Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy. Cancer Gene Ther. 15:723–732. 2008. View Article : Google Scholar : PubMed/NCBI
17	Lin G, Zhao L, Yin F, et al: TCF3 inhibits F9 embryonal carcinoma growth by the down-regulation of Oct4. Oncol Rep. 26:893–899. 2011.PubMed/NCBI
18	Afzal S, Jensen SA, Vainer B, et al: MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 20:1660–1666. 2009. View Article : Google Scholar : PubMed/NCBI
19	Lü MH, Liao ZL, Zhao XY, et al: hTERT-based therapy: A universal anticancer approach (Review). Oncol Rep. 28:1945–1952. 2012.PubMed/NCBI
20	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
21	García-Sáez AJ: The secrets of the Bcl-2 family. Cell Death Differ. 19:1733–1740. 2012.
22	Ola MS, Nawaz M and Ahsan H: Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
23	Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar : PubMed/NCBI
24	Würstle ML, Laussmann MA and Rehm M: The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res. 318:1213–1220. 2012.
25	Rosen A and Casciola-Rosen L: Macromolecular substrates for the ICE-like proteases during apoptosis. J Cell Biochem. 64:50–54. 1997. View Article : Google Scholar : PubMed/NCBI